Objectives: (1) To determine the prevalence of interstitial lung disease (ILD) and isolated low diffusing capacity for carbon monoxide (DLCO) in a large cohort of outpatients with dermatomyositis. (2) To compare the pulmonary abnormalities of patients with classic dermatomyositis and those with skin-predominant dermatomyositis.
Design: Retrospective cohort study.
Setting: University hospital outpatient dermatology referral center. Patients Medical records of 91 outpatients with adult-onset dermatomyositis seen between May 26, 2006, and May 25, 2009, were reviewed.
Main Outcome Measures: Presence of ILD on thin-slice chest computed tomographic (CT) scans and DLCO.
Results: Of the 71 patients with dermatomyositis who had CT or DLCO data, 16 (23%; 95% confidence interval [CI], 13%-33%) had ILD as defined by CT results [corrected]. All patients with ILD had a reduced DLCO, and the ILD prevalence was not different between patients with skin-predominant dermatomyositis (10 of 35 [29% ]) and those with classic dermatomyositis (6 of 36 [17% ]) (P = .27). Eighteen of 71 patients with dermatomyositis (25%; 95% CI, 15%-36%) (7 of 35 [20%] with skin-predominant dermatomyositis; 11 of 36 [31%] with classic dermatomyositis; P = .41) had a low DLCO in the absence of CT findings showing ILD. The prevalence of malignant disease was higher in patients with classic dermatomyositis than in those with skin-predominant dermatomyositis (P = .02), and no patients with skin-predominant dermatomyositis had internal malignant disease.
Conclusions: Radiologic ILD and isolated DLCO reductions, which may signify early ILD or pulmonary hypertension, are common in dermatology outpatients with both classic and skin-predominant dermatomyositis. Because DLCO testing is both inexpensive and sensitive for pulmonary disease, it may be appropriate to screen all patients with dermatomyositis with serial DLCO measurements and base further testing on DLCO results.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010864 | PMC |
| http://dx.doi.org/10.1001/archdermatol.2010.134 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
January 2025
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:
Background: Dermatomyositis is a chronic autoimmune disease with distinctive cutaneous eruptions and muscle weakness, and the pathophysiology is characterised by type I interferon (IFN) dysregulation. This study aims to assess the efficacy, safety, and target engagement of dazukibart, a potent, selective, humanised IgG1 neutralising monoclonal antibody directed against IFNβ, in adults with moderate-to-severe dermatomyositis.
Methods: This multicentre, double-blind, randomised, placebo-controlled, phase 2 trial was conducted at 25 university-based hospitals and outpatient sites in Germany, Hungary, Poland, Spain, and the USA.
Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study.
JID Innov
January 2025
Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
Article Synopsis
- - Dermatomyositis (DM) is a rare autoimmune disease affecting the skin and is often difficult to treat, with standard medications sometimes ineffective; lenabasum, a selective cannabinoid receptor 2 agonist, shows promise in managing these skin-related symptoms.
- - In a study involving a 3-year open-label extension of a Phase 2 trial with 20 patients resistant to traditional treatments, researchers assessed the long-term effectiveness and recurrence of DM symptoms while on lenabasum.
- - Results indicated significant improvements in skin disease activity and stability, with 58.3% of patients maintaining stable conditions and a notable reduction in flare-ups, suggesting lenabasum as a viable treatment for difficult-to-manage DM cases. *
Updates in Dermatomyositis: Newer Treatment Options and Outcome Measures From Dermatologic Perspectives.
Ann Dermatol
October 2024
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA.
Article Synopsis
- Dermatomyositis (DM) is a rare autoimmune disease that primarily affects the skin and can involve muscles, with new classification systems recognizing skin-dominant forms.
- Recent research has improved our understanding of the disease’s mechanisms and the role of specific autoantibodies, leading to the development of new treatments.
- This report focuses on recent advancements in treatments and outcome measures for DM, particularly from a dermatological perspective.
Purpose Of Review: This review addresses the challenges and advances in clinical endpoints for myositis, with a particular focus on ensuring comprehensive assessment of both muscle and skin disease activity. The relevance of this review stems from recent developments in outcome measures and their implications for clinical trial design and patient inclusivity. While quality of life (QoL) and lung involvement are also important aspects of myositis, they are beyond the scope of this review and need to be addressed in future studies.
View Article and Find Full Text PDFCurrent myositis clinical trials and tribulations.
Ann Rheum Dis
June 2024
Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA
Article Synopsis
- Increased understanding of disease mechanisms and outcome measures has led to a surge in idiopathic inflammatory myopathies clinical trials, averaging five trials per site in the past three years.* -
- Despite the positive momentum, there are concerns about trial designs, including competition among trials, lengthy placebo periods, and the underrepresentation of minority groups among participants.* -
- The viewpoint emphasizes the need for patient input in trial designs and proposes innovative approaches to address issues like outdated classification criteria and the effectiveness of existing outcome measures.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!